Acrivon Therapeutics, Inc.

Healthcare · Biotechnology · United States

Last price 1.66 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 71.14M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Acrivon Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops oncology medicines for patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its generative phosphoproteomics platform. The company operates Acrivon Predictive Precision Proteomics (AP3), a precision medicine platform that enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is AC...